Maintaining Investments in New Innovation Act

Refreshed 1 h ago

Introduced 2025-02-27Topic: health care

Summary

Summary by the Congressional Research Service

Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Full text and official record on Congress.gov

Action history

Date	Chamber	Action	Status effect
2025-02-27	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.	refer
2025-02-27	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.	refer
2025-02-27		Introduced in House	introduce
2025-02-27		Introduced in House	introduce

Summary

Sponsors

Action history